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                                                 Introduction 
Tuberculosis is a global emergency. One third of the world's population is 
infected, and although only about 5–10% develops active disease during the 
first few years following exposure 1, this still results in a massive case load, 
with eight million new cases each year, and three million deaths. Moreover, the 
percentage that progresses to disease is increasing. Tuberculosis is one of the 
first secondary infections to be activated in human immunodeficiency virus 
(HIV)-positive individuals 4.  
Moreover the stresses of poverty, malnutrition and war, increase the rate 
of reactivation for reasons discussed later. Even in developed countries such as 
the United Kingdom, the disease distribution in large cities parallels the 
distribution of poverty 3. Meanwhile the breakdown of healthcare systems is 
leading to incomplete case and contact tracing, incomplete treatment, and 
increases in drug resistance. In some parts of the world, many of the available 
drugs are fake or out of date 4. In many areas, existing treatment is probably 
doing more harm than good, as incomplete treatment regimens select for drug 
resistance.  
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Multidrug-resistant tuberculosis is spreading at an alarming rate, 
especially in a developing country like our India. There were more cases of 
tuberculosis in 2005 than ever before in the history of mankind.  
We need new insights that lead to more rapid therapies and immuno 
therapies, and more reliable vaccines. Recent insights have come from, 
understanding of the relationship between Mycobacterium tuberculosis and 
macrophages; the multiple T cell types that recognize mycobacterial peptides, 
lipids and glycolipids; the critical role of interferon γ and interleukin-12 (IL-12) 
in human mycobacterial infection revealed by genetically defective children; 
quantization of the presence and importance of Th2 lymphocyte activation in 
human tuberculosis; the role of local conversion of inactive cortisone to active 
cortisol in the lesions; the recognition that some effective prophylactic vaccines 
also work as immunotherapeutic whereas others do not. In the longer term the 
recent sequencing of the M. tuberculosis genome will lead to further advances.  
 Pulmonary tuberculosis is an important clinical problem as about one 
third of the world’s population is infected with Mycobacterium tuberculosis and 
tuberculosis continues to be a leading infectious disease worldwide. The current 
vaccine Mycobacterium bovis bacilli Calmette & Guerin (BCG), has variable 
protective efficacy, ranging from 0 to 85% in different studies 2. Owing to the 
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variable efficacy and threat of disease in an immuno compromised host, the use 
of a live vaccine, BCG, is still a controversial subject. In this context the use of 
second generation anti-TB vaccines and alternative immunomodulatory 
approaches to treatment are urgently required.  
 
Also, understanding the cellular and molecular basis of the protective 
memory immune response against M. tuberculosis would assist in designing 
new vaccines. There is compelling clinical evidence that, in addition to innate 
virulence of tubercle bacillus itself, the host response to M. tuberculosis plays a 
major role in determining the clinical manifestations and the ultimate outcome 
of the patients who encounter this pathogen 4.  
 
  Understanding the components of the host response at a basic level is 
likely to lead to a better understanding of the pathogenesis of TB in humans and 
result in better and novel approaches to prevention and therapy of this disease.  
 
            Among the many clinical manifestations of tuberculosis, tuberculous 
pleuritis is of particular interest. Host defence against Tuberculosis involves 
infiltration of the peripheral blood mononuclear cells (PBMC) into pleural 
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space 5. Patients with TB mount a resistant immune response to infection, 
reflected by resolution of pleuritis even without chemotherapy in most cases7. 
Thus TB provides a very good model to study immune response in vivo, as the 
immunological reactivity against M. tuberculosis is compartmentalised in 
pleural space 8. 
 
 It is known that the critical component of protective immunity against 
TB is T cell-mediated response characterised by secretion of cytokines, 
primarily by the CD4+ T cells 9. 
 
Knowing the cellular and humoral responses at the site of infection could 
give us a better understanding of the immune responses involved therein. 
Inflammatory cells and pleural fluid (PF) can readily be obtained from the 
infection site and characterisation of PF derived cell population and cytokines 
released could help us to gain further insight into the immunomodulatory 
processes involved in this disease. Hence it is decided to study immune 
responses in TB and a comparison of the systemic and local immune responses 
in such patients. 
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OBJECTIVES OF THE STUDY 
 
1. To study immune responses in Tuberculosis with respect to Th1 and Th2   
immunity, so that in future immunotherapy of Tuberculosis can be 
targeted. 
 
2. To compare the systemic and local immune responses in tuberculous 
pleural effusion patients. 
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REVIEW OF LITERATURE 
Incidence of tuberculosis is increasing. Current treatment regimens 
require at least 6 months, because latent or stationary phase organisms are 
difficult to kill. Such regimens do not achieve full compliance, and "directly 
observed therapy short course" (DOTS) is having less impact than expected.23 
This worrying situation is aggravated by co infection with human 
immunodeficiency virus (HIV), and by the increase in drug-resistant strains. 
  
      An important reason for the current failure to control tuberculosis is the 
fact that even the best available treatment must be continued for at least 6 
months. This treatment regimen is not a realistic proposition in most developing 
countries, or even in the inner cities of rich ones, because the patients feel well 
after a few weeks and stop taking the drugs. The World Health Organization 
(WHO) now admits that directly observed therapy short-course (DOTS), in 
which the patient is supervised while taking every dose of therapy, helps but 
does not solve the problem 23.  
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Persistent bacilli and latent infection are two interrelated reasons for the 
requirement for 6 month regimens. The first is obvious and often discussed. The 
chemotherapy kills the vast majority of the bacteria within a few days, but there 
are subpopulations of "persisters" 23. It is not clear whether these organisms are 
in true stationary phase 10 or merely replicating extremely slowly. Nor is it clear 
where they are located. Most authors assume that they are in old lesions or sites 
of fibrosis or calcification, where oxygen availability may be low. However, in 
a forgotten paper published in 1927, Opie and Aronson reported that 80% of 
tuberculous lesions were already sterile 5 yrs after the primary infection, 
whereas live bacilli could be found in macroscopically normal lung tissue. The 
fact that metronidazole, a drug that should be active under anaerobic conditions, 
is not active in a model of latent tuberculosis infection in mice, implies that live 
organisms also persist in well-oxygenated sites in this species 11. 
 
 
Not only do persister organisms cause problems for treatment, but they 
also constitute an important source of infection. They can persist for the rest of 
the life of the individual 10, and, at least in countries with low or moderate 
tuberculosis endemicity, many cases of tuberculosis result from reactivation of 
latent infection11.  
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Tuberculosis in humans
A key issue is to understand why individuals infected with 
M. tuberculosis experience different clinical outcomes 
INTRACELLULAR pathogen (facultative extracellular)
Exposed
Infected 
(2 billion, 8 
million new 
cases per year)
Primary
TB
Latent 
TB Reactivation
30%
80-90%
5-10%
5-10%
Clearance
70%
Death
(2 million)
 
   Clinical Outcome of Tuberculosis 
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PATHOGENESIS 
Mycobacterium tuberculosis is an obligatory aerobic, intracellular 
pathogen, which has a predilection for the lung tissue rich in oxygen supply. 
The tubercle bacilli enter the body via the respiratory route. The bacilli spread 
from the site of initial infection in the lung through the lymphatics or blood to 
other parts of the body, the apex of the lung and the regional lymph node being 
favoured sites. Extrapulmonary TB of the pleura, lymphatics, bone, genito-
urinary system, meninges, peritoneum, or skin occurs in about 15 per cent of 
TB patients.  
 
Events following entry of bacilli: 
Phagocytosis of M.tuberculosis by alveolar macrophages is the first event 
in the host-pathogen relationship that decides outcome of infection. Within 2 to 
6 wk of infection, cell-mediated immunity (CMI) develops, and there is an 
influx of lymphocytes and activated macrophages into the lesion resulting in 
granuloma formation. The exponential growth of the bacilli is checked and dead 
macrophages form a caseum. The bacilli are contained in the caseous centers of 
the granuloma. The bacilli may remain forever within the granuloma, get re-
activated later or may get discharged into the airways after enormous increase 
in number, necrosis of bronchi and cavitations.  
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Fibrosis represents the last-ditch defense mechanism of the host, where it 
occurs surrounding a central area of necrosis to wall off the infection when all 
other mechanisms failed.  
 
Macrophage-Mycobacterium interactions and the role of macrophage in 
host response can be summarized under the following headings: 
1. Surface binding of M. tuberculosis to macrophages. 
2.  Phagosome-lysosome fusion. 
3.  Mycobacterial growth inhibition/killing. 
4.  Recruitment of accessory immune cells for local inflammatory 
response and presentation of antigens to T cells for development of 
acquired immunity. 
 When exudative pleural effusions accumulate in the pleural space, 
various cells produce many kinds of cytokines or chemokines that contribute to 
the progress of pleuritis 15  
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Dynamics of the Immune Response
  Dynamics of Immune Response in Tuberculosis 
On encountering an antigen, naïve CD4+ T-helper precursor cells enact a 
specific process that results in differentiation toward the T-helper type 1(Th1) 
or T-helper type 2 (Th2) lineages. Th1 cells produce interleukin (IL)-2 and 
interferon γ whereas Th2 cells produce IL-4, IL-5, and IL-10.  
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Th1 and Th2 dichotomy in TB:  
Two broad (possibly overlapping) categories of T cells have been 
described, Th1 type and Th2 type, based on the pattern of cytokines they 
secrete, upon antigen stimulation.  
Th1 cells secrete IL-2, IFN-γ and play a protective role in intracellular 
infections.  
Th2 type cells secrete IL-4, IL-5 and IL-10 and are either irrelevant or 
exert a negative influence on the immune response.  
The balance between the two types of response is reflected in the 
resultant host resistance against infection. The type of Th0 cells shows an 
intermediate cytokine secretion pattern. The differentiation of Th1 and Th2 
from these precursor cells may be under the control of cytokines such as IL-12. 
In mice infected with virulent strain of M. tuberculosis, initially Th1 like 
and later Th2 like response has been demonstrated 18. There are inconsistent 
reports in literature on preponderance of Th1 type of cytokines, of Th2 type, 
increase of both, decrease of Th1, but not increase of Th2 etc.  
 
Moreover, the response seems to vary between peripheral blood and site 
of lesion; among the different stages of the disease depending on the severity.  
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It has been reported that PBMC from TB patients, when stimulated in 
vitro with PPD, release lower levels of IFN-γ and IL-2, as compared to 
tuberculin positive healthy subjects 13. Other studies have also reported reduced 
IFN-γ 14 increased IL-4 secretion 14 or increased number of IL-4 secreting cells 
15
. These studies concluded that patients with TB had a Th2type response in 
their peripheral blood, whereas tuberculin positive patients had a Th1-type 
response.  
 
More recently, cellular response at the actual sites of disease has been 
examined. Zhang et al studied cytokine production in pleural fluid and found 
high levels of IL-12 after stimulation of pleural fluid cells with M. tuberculosis. 
IL-12 is known to induce a Th1-type response in undifferentiated CD4+ cells 
and hence there is a Th1 response at the actual site of disease. The same group 
17
 observed that TB patients showed evidence of high IFNγ production and no 
IL4 secretion by the lymphocytes in the lymph nodes.  
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There was no enhancement of Th2 responses at the site of disease in 
human TB. Robinson et al 18 found increased levels of IFN-γ mRNA in situ in 
BAL cells from patients with active pulmonary TB.  
 
In addition, reports suggest that in humans with TB, the strength of the 
Th1-type immune response relate directly to the clinical manifestations of the 
disease. Sodhi et al 19 have demonstrated that low levels of circulating IFN-γ in 
peripheral blood were associated with severe clinical TB. Patients with limited 
TB have an alveolar lymphocytosis in infected regions of the lung and these 
lymphocytes produce high levels of IFN-γ 20. In patients with far advanced or 
cavitary disease, no Th1-type lymphocytosis is present.  
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New 2-compartmental model: LUNG + LN
Compartments
Lung (L) and draining 
Lymph Node (LN)
New variables
Dendritic Cells
IDC (immature, Lung)
MDC (mature, LN)
Lymphocytes (in the LN)
ThP (Precursor Helper Ts)
T (Naïve T cells)
Simeone Marino and Denise E. Kirschner. The Human Immune Response to Mycobacterium tuberculosis in 
Lung and Lymph Node. J Theor Biol. 2004 Apr 21;227(4):463-86. 
Simeone Marino, Pawar S., Fuller CL, Reinhart TA, Flynn JL and Kirschner DE, Dendritic Cell Trafficking and 
Antigen Presentation in the Human Immune Response to Mycobacterium tuberculosis. J. Immunol. 2004 in press
   
Human Immune Response to Mycobacterium tuberculosis 
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Cytokines  
Interferon-γ:  
IFN-γ, a key cytokine in control of M. tuberculosis infection is produced 
by both CD4+ and CD8+ T cells, as well as by NK cells. IFN-γ might augment 
antigen presentation, leading to recruitment of CD4+ T-lymphocytes and/or 
cytotoxic T-lymphocytes, which might participate in mycobacterial killing. 
Although IFN-γ production alone is insufficient to control M. tuberculosis 
infection, it is required for the protective response to this pathogen. IFN-γ is the 
major activator of macrophages and it causes mouse but not human 
macrophages to inhibit the growth of M. tuberculosis in vitro 19. IL-4, IL-6 and 
GM-CSF could bring about in vitro killing of mycobacteria by macrophages 
either alone or in synergy with IFN-γ in the murine system1 17. IFN-γ GKO 
mice are most susceptible to virulent M. tuberculosis 21.  
 
Humans defective in genes for IFN-γ or the IFN γ receptor are prone to 
serious mycobacterial infections, including M. tuberculosis 19.  
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Although IFN-γ production may vary among subjects, some studies 
suggest that IFN-γ levels are depressed in patients with active TB 20. Another 
study demonstrated that M. tuberculosis could prevent macrophages from 
responding adequately to IFN-γ 21. This suggests that the amount of IFN-γ 
produced by T cells may be less predictive of outcome than the ability of the 
cells to respond to this cytokine.  
 
One study comparing the immune response to pre-and post- BCG 
vaccination, has shown that BCG had little effect in driving the immune 
response towards IFN-γ and a protective Th1 response 18. In another study on 
tuberculous pleuritis, a condition which may resolve without therapy, a 
protective Th1 type of response with increased IFN-γ is seen at the site of lesion 
(pleural fluid), while a Th0 type of response with both IFN-γ and IL-4 is seen 
under in vitro conditions 18.  
 
To determine if the manifestations of initial infection with M. 
tuberculosis reflect changes in the balance of T cell cytokines, it was evaluated 
in vitro cytokine production of children with TB and healthy tuberculin reactors 
24
. FN-γ production was most severely depressed in patients with moderately 
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advanced and far advanced pulmonary disease and in malnourished patients. 
Production of IL-12, IL-4 and IL-10 was similar in TB patients and healthy 
tuberculin reactors. These results indicate that the initial immune response to M. 
tuberculosis is associated with diminished IFN-γ production, which is not due to 
reduced production of IL-12 or enhanced production of IL-4 or IL-10.  
 
Tumor necrosis factor (TNF-α):  
TNF-α is believed to play multiple roles in immune and pathologic 
responses in TB.  M. tuberculosis induces TNF-α secretion by macrophages, 
dendritic cells and T cells. In mice deficient in TNF−α or the TNF receptor, M. 
tuberculosis infection resulted in rapid death of the mice, with substantially 
higher bacterial burdens compared to control mice. TNF-α in synergy with 
IFN-γ induces NOS2 expression 25.  
 
TNF-α is important for walling off infection and preventing 
dissemination. Convincing data on the importance of this cytokine in granuloma 
formation in TB and other mycobacterial diseases has been reported 21. TNF-α 
affects cell migration and localization within tissues in M. tuberculosis 
infection. TNF-α influence expression of adhesion molecules as well as 
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chemokines and chemokines receptors, and this is certain to affect the 
formation of functional granuloma in infected tissues.  
 
TNF-α has also been implicated in immuno pathologic response and is 
often a major factor in host-mediated destruction of lung tissue 27. In one study, 
increased level of TNF-α was found at the site of lesion (pleural fluid), as 
compared to systemic response (blood) showing that the compartmentalized 
immune response must be containing the infection 8 
 
Interleukin-1: 
 IL-1, along with TNF-α, plays an important role in the acute phase 
response such as fever and cachexia, prominent in TB. In addition, IL-1 
facilitates T lymphocyte expression of IL-2 receptors and IL-2 release. The 
major antigens of mycobacteria triggering IL-1 release and TNF-α have been 
identified 29. IL-1 has been implicated in immunosuppressive mechanisms 
which is an important feature in immunity of tuberculosis 30 
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Interleukin-2: 
  IL-2 has a pivotal role in generating an immune response by inducing an 
expansion of the pool of lymphocytes specific for an antigen. Therefore, IL-2 
secretion by the protective CD4 Th1 cells is an important parameter to be 
measured and several studies have demonstrated that IL-2 can influence the 
course of mycobacterial infections, either alone or in combination with other 
cytokines 27. 
 
Interleukin-4: 
  Th2 responses and IL-4 in TB are subjects of some controversy. In 
human studies, a depressed Th1 response, but not an enhanced Th2 response 
was observed in PBMC from TB patients. Elevated IFN-γ expression was 
detected in granuloma within lymph nodes of patients with tuberculous 
lymphadenitis, but little IL-4 mRNA was detected 31. These results indicated 
that in humans a strong Th2 response is not associated with TB. Data from mice 
studies suggest that the absence of a Th1 response to M. tuberculosis does not 
necessarily promote a Th2 response and an IFN γ deficiency, rather than the 
presence of IL-4 or other Th2 cytokines, prevents control of infection. In a 
study of cytokine gene expression in the granuloma of patients with advanced 
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TB by in situ hybridization, IL-4 was detected in 3 of 5 patients, but never in 
the absence of IFN-γ expression 72. The presence or absence of IL-4 did not 
correlate with improved clinical outcome or differences in granuloma stages or 
pathology.  
 
Interleukin-6: 
 IL-6 has also been implicated in the host response to M. tuberculosis. 
This cytokine has multiple roles in the immune response, including 
inflammation, hematopoiesis and differentiation of T cells. A potential role for 
IL-6 in suppression of T cell responses was reported 33. Early increase in lung 
burden in IL-6 -/-mice suggests that IL-6 is important in the initial innate 
response to the pathogen 37.  
 
Interleukin-10:  
IL-10 is considered to be an anti inflammatory cytokine. This cytokine, 
produced by macrophages and T cells during M. tuberculosis infection, 
possesses macrophage-deactivating properties, including down regulation of IL-
12 production, which in turn decreases IFN-γ production by T cells. IL-10 
directly inhibits CD4+ T cell responses, as well as by inhibiting APC functions 
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of cells infected with mycobacteria1 species 33. Transgenic mice constitutively 
expressing IL-10 were less capable of clearing a BCG infection, although T cell 
responses including IFN-γ production were unimpaired 34. These results 
suggested that IL-10 might counter the macrophage activating properties of 
IFN-γ. 
Interleukin-12:  
IL-12 is induced following phagocytosis of M. tuberculosis bacilli by 
macrophages and dendritic cells, which leads to development of a Th1 response 
with production of IFN-γ. IL-12p40-gene deficient mice were susceptible to 
infection and had increased bacterial burden, and decreased survival time, 
probably due to reduced IFNγ production 37. Humans with mutations in IL-
12p40 or the IL-12R genes present with reduced IFN-γ production from T cells 
and are more susceptible to disseminated BCG and M. avium infections 35. An 
intriguing study indicated that administration of IL-12 DNA could substantially 
reduce bacterial numbers in mice with a chronic M. tuberculosis infection 36, 
suggesting that induction of this cytokine is an important factor in the design of 
a TB vaccine.  
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McDyer et al found that stimulated PBMC from MDR-TB patients had 
less secretion of IL-2 and IFNγ than did cells from healthy control subjects. 
IFNγ production could be restored if PBMC were supplemented with IL-12 
prior to stimulation and antibodies to IL-12 caused a further decrease in IFNγ 
upon stimulation. Taha et al demonstrated that in patients with drug susceptible 
active TB both IFN-γ and IL-12 producing BAL cells were abundant as 
compared with BAL cells from patients with inactive TB. 
 
Cell Mediated Immunity 
So, tuberculosis is a granulomatous disorder, and the cellular immune 
response plays an important role in the defense mechanism. CD4 T-cells in 
tuberculous pleural effusions are Th1 dominant and are activated enough to 
produce Th1 cytokines.  It was recently reported that the concentrations of IFN 
γ are all higher in tuberculous pleural effusions than in malignant pleural 
effusions IL-12 is known to induce a Th1 response in undifferentiated CD4+ 
cells, and this supports Th1 dominance at the morbid site of tuberculosis 36. In 
Mycobacterium tuberculosis infections, IL-18 is also produced by activated 
macrophages and induces IFN-γ in synergy with IL-12cytokine status and T-
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cell reactivity within the tuberculous pleural effusions were polarized strongly 
toward a Th1 response 
 
The ability to manipulate the immune system of mice with neutralizing 
antibodies or gene knockout has provided strong evidence that in this species, 
immunity to tuberculosis correlates with a Type 1 response. In vivo T-helper 
(Th) 1 or Th2 cells act in concert with CD8 cells, and with numerous other cell 
types including macrophages, B cells and some stromal cells. Collectively these 
give rise to two patterns of cytokine release known as Type 1 (dominated by 
interleukin-2 (IL-2), interleukin-12 (IL-12), and interferon γ and Type 2 
(dominated by interleukin-(IL)-4, 5, and 13) 14, 15 
 
Disruption of the major histocompatibility complex (MHC) Class II 
genes or of the gene for the ß chain of the T cell receptor resulting in a 
deficiency of CD4+ T cells, render mice susceptible even to the avirulent 
Bacillus Calmette Guerin (BCG). Disruption of the gene for IFN γ makes mice 
very susceptible to M. tuberculosis (death within 3 weeks), and such mice may 
even die after many weeks from challenge with BCG. IL-18 knockout (KO) 
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mice are also more susceptible, perhaps because IL-18 contributes to the 
induction of IFN γ expression.  
 
A major inducer of the Type 1 pathway is IL-12. The exact role of this 
cytokine depends on the mouse strain , but IL-12 KO mice are more susceptible 
to tuberculosis 16 
 
The detrimental role of Type 2 responses  
 Data emphasizes the crucial role of the Type 1 response. In agreement 
with this, other data indicate that the Type 2 response is not only unable to 
protect mice, but can seriously undermine the efficacy of the Type 1 response. 
If a weak Type 2 response to the shared mycobacterial antigens is deliberately 
induced before challenge, mice are found to be strikingly more susceptible to 
tuberculosis than are nonimmunised control animals 39.  
 
Similarly, in the Balb/c mouse model of pulmonary (tuberculosis) TB 
infection, the appearance of IL-4 in the lung lesions (as seen by immuno 
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histochemistry and reverse transcriptase-polymerase chain reaction (RT-PCR) 
coincides temporally and spatially with the appearance of areas of pneumonia 
and necrosis, leading to rapid clinical deterioration and death. These 
observations are not contradicted by the claim that, in IL-4 gene-disrupted mice, 
there is no evidence of increased resistance to the infection . First, such mice are 
not devoid of Type 2 cytokine activity because IL-13 can substitute for many 
functions of the knocked out gene. Secondly, the detrimental role of the Type 2 
response is most apparent in the late progressive phase of the disease, 
particularly after day 60 
 
Type 2 responses in human tuberculosis 
 
              These observations, and above all, the susceptibility of children with 
defective receptors for IFN γ or IL-12, provide definitive evidence of the 
importance of Type 1 cytokines, and suggest a close parallel with the mouse 
models. Recently, the negative role of Type 2 cytokines in human tuberculosis 
(TB), again paralleling the murine models, has been established 39. Expression 
of IL-4, whether measured by flow cytometry, or by sensitive quantitative RT-
PCR on unstimulated peripheral blood T cells 40, is increased and correlates 
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with severity of disease and with cavitation. The IL-4 mRNA copy number also 
correlates with total immunoglobulin-E (Ig E) and with levels of soluble CD30..  
 
Thus although it is true that actual cytokine levels and mRNA copy 
numbers are higher for Th1 than for Th2 cytokines in tuberculosis, the major 
change in cytokine expression compared to healthy donors is not as previously 
stated, the small decrease in expression of Th1 cytokines, but rather a massive 
(80–100-fold) increase in expression of Th2 cytokines 15 . This has resolved a 
long-running controversy which deserves explanation. That there is a Th2 
component in the response of human tuberculosis patients to M. tuberculosis 
ought to have been accepted 10 years ago, because there is no other known 
explanation for the presence of specific IgE antibody 27. 
 
 Interestingly, the other largely Type 2 cytokine-dependent antibody, 
immunoglobulin-G4 (IgG4) is also reported to be increased in patients. 
Similarly, immunohistochemistry reveals IL-4-expressing cells in the lymphoid 
tissue of tuberculosis patients (but not in tissue from patients with sarcoidosis).  
\ 
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PLEURAL EFFUSION 
Pleural effusions, or abnormal accumulations of fluid in the pleural 
space, can be caused by a wide variety of intra thoracic and systemic diseases. 
In some cases, the etiology of a pleural effusion is apparent from the clinical 
context (eg, bilateral pleural effusion in congestive heart failure). However, the 
causes and clinical significance of the effusions often are not obvious. In most 
of these patients, a definitive or presumptive identification of the cause can be 
determined through analysis of pleural fluid obtained through thoracentesis.  
 
Transudates are ultra filtrates of plasma in the pleura that arise from a 
small, defined group of causes. In contrast, exudates are produced by a variety 
of inflammatory conditions and often require more extensive evaluation and 
treatment 
Pathophysiology 
The inner surface of the chest wall and the surface of the lungs are 
covered by the parietal and visceral pleural, respectively, with a potential space 
of 10-24 µm between the 2 pleural surfaces. Normally, this space is filled with a 
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very small amount of fluid. However, large amounts of fluid can accumulate in 
the pleural space under pathological conditions. 
 The parietal pleura have sensory innervation and small apertures that aid 
in the absorption of particles and fluid. Both pleural surfaces mainly are 
supplied by systemic arterial vessels. Lymphatic vessels from the parietal pleura 
drain to lymph nodes along the anterior and posterior chest wall, while 
lymphatics from the visceral surface drain to the mediastinal lymph nodes. 
Normally, the pleural space contains a small amount of a colorless alkaline fluid 
(0.1-0.2 mL/kg), which has a low amount of protein (<1.5 g/dL). 
Approximately 90% of accumulated fluid in the pleural space is drained by the 
venous side, while the other 10% is absorbed by the 
lymphatics.  
A delicate balance between the oncotic and hydrostatic pressures of the 
pleural space and the capillary intravascular compartments regulates filtration 
and drainage of pleural fluid. Hydrostatic and oncotic pressures are many-fold 
higher in the plasma than in the pleural space, but the net absorption of pleural 
fluid is slightly higher than the net filtration forces. In addition, the lymphatic 
drainage from the parietal pleura can surpass the rate of fluid filtration in the 
pleural space by several folds.  
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Chest wall and diaphragmatic movements enhance absorption of pleural 
fluid by the vascular and lymphatic vessels. Excessive filtration of fluid can 
overwhelm these efficient absorptive mechanisms and lead to the formation of 
pleural effusion.  
Pleural effusions usually are classified as transudates and exudates. 
Diseases that affect the filtration of pleural fluid result in transudates formation, 
such as in congestive heart failure and nephritis. Transudates usually occur 
bilaterally because of the systemic nature of the causative disorders. 
Inflammation or injury increases pleural membrane permeability to proteins and 
various types of cells and leads to the formation of exudative effusion.  
 
Mycobacterium tuberculosis invades the pleural cavity chiefly through 
rupture of sub pleural caseous foci within 6 to 12 weeks after a primary 
infection. Bacillus protein antigens seem to induce a delayed hypersensitivity 
reaction that stimulates lymphocytes, which in turn release certain lymphokines 
that (1) activate macrophages against the mycobacterium and (2) alter the 
permeability of pleural vessels and affect the formation of granuloma. 
Tuberculous pleural effusion (TPE) is an acute granulomatous pleurisy caused 
by recent infection by the mycobacterium. Patients with TPE invariably have a 
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small sub pleural nidus of tuberculosis showing fibrous and granulomatous 
inflammation and clear signs of leakage into the pleural space. Although TPE 
can resolve spontaneously within a few weeks or months, about one third of 
persons with untreated TPE subsequently develop a more serious form of 
tuberculosis.  
Tuberculous pleural effusions are not always easy to diagnose because 
the standard criterion (the presence of a lymphocyte-rich exudates associated 
with caseous necrotic granuloma in pleural biopsy tissue samples, positive 
Ziehl-Neelsen stains or Lowenstein cultures of effusion or tissue samples, and 
cutaneous sensitivity to purified tuberculin protein antigen derivative [PPD]) is 
not invariably satisfied 6. 
 
In recent years, numerous authors studied possible biochemical markers 
such as adenosine deaminase (ADA), ADA isoenzymes, lysozyme, interferon 
gamma, and other lymphokines to improve diagnostic efficiency, but diagnosis 
is still sometimes difficult.  
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Materials and methods  
Study subjects:  
Blood and PF were collected from 51 patients from our wards before the 
start of the treatment. The mean age of the study subjects was 38 years (range 
18- 65 years). These patients were seronegative for human immunodeficiency 
virus (HIV).The blood and the PF samples collected for diagnostic and 
therapeutic purposes were utilised for the study. A written and informed 
consent was obtained from each patient. The collection of the samples and the 
study followed the ethical guidelines of Government General Hospital, 
Chennai.  
Pleural effusions were defined as exudative using Light’s criteria.  
Light’s criteria  
The pleural fluid is an exudate if one or more of the following criteria are met:  
• Pleural fluid protein divided by serum protein >0.5 
• Pleural fluid LDH divided by serum LDH >0.6 
• Pleural fluid LDH more than two-thirds the upper limits of normal serum 
LDH 
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 Of the total, 51 patients were diagnosed to have tuberculosis based on 
the 
1. Smear for AFB 
2. Culture of the fluid (BACTEC) 
3. Polymerase chain reaction (PCR) positivity (IS6110 specific) of the sputum 
or the PF together with the clinical picture. 
These 31 patients showed positivity in at least any two of the above 
criteria and hence were categorised as TB group.  
 
Non TB group  
The remaining 20 patients, belonging to the Non TB group had exudative 
effusion with lymphocytic predominance due to causes other than tuberculosis. 
These patients had  
1. Malignancy (N = 13) 
          2. Parapneumonic effusion (N = 4)  
          3. Exudative effusion due to secondary infections in SLE (N = 3) 
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All infectious but non-tuberculous pleural effusion was culture proven. 
The diagnosis of malignancy was on the basis of histology and cytology. Other 
cases were diagnosed based on compatible clinical and radiological findings. 
The diagnosis was also retrospectively proven as the disease was cured 
following the appropriate therapy.  
 
In vivo and in vitro cytokine assay  
Plasma (BL) and PF obtained from 51 patients were processed within 
30min and were stored at 37 degree C, for measuring the in vivo cytokine 
levels. For in vitro cytokines, the PBMC and PFMC of the same 32 patients, at 
the concentration of 0.5U106 cells ml31 were cultured in 48-well plates 
(Costar, Cambridge, MA, USA) with antigens (PPD, CF, MTB, 10 Wgml31) or 
without antigens that served as control. The supernatants were collected after 48 
h, when the maximum cytokine levels were found in initial standardization 
experiments. The cell-free supernatants were stored at 37 degree C for the 
cytokine assessment.  
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BL, PF and the supernatants of PBMC and PFMC were thawed at the 
time of cytokine enzyme-linked immunosorbent assay (ELISA). Measurement 
of interferon (IFN)-gamma, tumor necrosis factor (TNF) alpha, interleukin (IL)-
12 p40 and IL-4 were done using the sandwich ELISA kit, according to the 
manufacturer’s instruction (RpD Systems). The average of the duplicate 
readings was taken as the final concentration. 
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Cytokines (Lung)
   Formulae Used for Measurement of Cytokines 
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Isolation of cells  
PBMC and the PF mononuclear cells (PFMC) were isolated by Ficoll 
Hypaque (Amersham Pharmacia) density gradient centrifugation. The cells 
were washed twice in 1U Hank’s balanced salt solution (HBSS) (Whittaker). A 
final re suspension was made in RPMI-1640(Sigma Chemicals Co.), 
supplemented with 10% autologous sera, to the required concentration.  
 
Flow cytometry analysis  
We studied the percentage of various cell populations in PBMC and 
PFMC of 49 patients (31 TB and 18 NTB) by flow cytometric analysis. 100µl 
of the cell suspension containing 105 cells was washed with phosphate-buffered 
saline (PBS). A five-tube panel consisting of unstained cells, isotype control 
(mouse IgG conjugated to fluorescein thiocyanate (FITC) and Phycoerythrin 
(PE)), T cells/B cells marker (CD3 FITC/CD19 PE), helper T cells/cytotoxic T 
cells marker (CD4 FITC/CD8 PE), T cells/natural killer (NK) cells marker 
(CD3 FITC/CD16+56 PE), respectively were chosen. The cells were incubated 
with these monoclonal antibodies for 30min at 4‡C. Cell samples were washed 
twice with PBS and washed in 1% (w/v) paraformaldehyde. Cells were 
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acquired within 24 h, using the fluorescence-activated cell scan FAC Scan 
(Becton Dickinson)and the analyses were done using Cell Quest software.  
 
   The data were expressed as percentage of total lymphocytes. A total of 
10 000 events for each sample were acquired. Fluorescence compensation on 
the flow cytometry was adjusted to minimize the overlap of the FITC and PE 
signals. 
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T helper cells (Lung)
 
Formulae Used for calculation of T cells                        
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Statistical analysis  
 
Data are presented as the mean and S.E.M. in both text and in figures. 
For normally distributed data, comparisons between groups were done with the 
paired or unpaired Student’s t-test, as appropriate. For data that were not  
normally distributed, the Wilcoxon rank sum test was used. P < 0.05 was 
considered to be statistically significant. 
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 Results and discussion  
The rising prevalence of tuberculosis compounded by the increase in HIV 
infection and the emergence of drug-resistant strains of M. tuberculosis urge the 
need for better vaccines. The immune response against tuberculosis is known to 
be primarily cell mediated.  
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A. Cell Subset profile of 30 Tuberculosis patients 
(Mean and S.E.M are represented in the graph;  
Statistical significance is marked by *) 
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B. Cell Subset of 21 Non Tuberculosis Patients 
(Mean levels and S.E.M are shown in the graph) 
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Understanding the immune responses from a diverse group of patient 
population, especially the TB patients, would help us to understand the 
protective immune responses operating at local levels. To identify newer 
antigens that specifically elicit protective immune responses at a local site 
compared to that at the systemic level would be a substantial candidate for the 
development of new generation TB vaccines.  
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To start with, we investigated the in vivo correlates of immunity by 
studying the immunological architecture in PF and blood. Our flow cytometric 
data showed that there is an increase in the percentage of CD4 cells (P < 0.05) 
in PF as compared to that of blood in TB patients (Fig. A). Also there was an 
increase in the CD4/CD8 ratio in TB patients (Fig. C). A representative of these 
data acquired on flow cytometer is depicted in Fig. D.  
 
The percentage of CD8 cytotoxic T cells in blood and PF of TB patients 
was higher than the control NTB cases (Fig. A and B). This marginal increase 
in percentage of CD8 T cells could be compensatory, in response to increased 
percentage of CD4 cells, a mechanism to maintain the CD4/CD8 ratio and an 
additional ‘acquired’ activation by these cells to control infection [12]. The 
distinct scenario of the CD4 T cells admixed with the CD8 cytotoxic T cells 
suggests that the lead role in CMI is played by the CD4 T cells. This is evident 
from the higher CD4/CD8 ratio seen with TB patients. The population of the 
CD16+56 NK cells showed a decrease at the local site of TB patients, 
indicating that the CD8 T cells might have a compensatory role to play in the 
cytotoxic killing of infected cells. The percentage of CD19 B cells was low in 
PFMC compared to PBMC, indicating a lack of enhanced B cell response in PF. 
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The higher CD4 cells in the PF and a greater CD4/CD8 ratio in TB patients is 
due to compartmentalisation, which is unique to TB and our results agree with 
it. 
 
To evaluate further in vivo correlates of immunity at the site of infection, 
we measured the cytokine levels in the PF and in the BL that would reflect the 
in vivo helper T cell response in tuberculosis. Our results showed that there is 
selective concentration of IFN-gamma, TNF-alpha and IL-12 in the PF of TB 
patients (Fig. 3A), as reported by the previous studiesThis confirms that the 
TH1 type cytokine and hence TH1 type immune response occurs at the site of 
disease. The absence of any compartmentalised pattern of in vivo cytokine in 
NTB subjects (Fig. 3B) is because of the absence of mycobacteria or its 
antigens in the pleura unlike TB, where the T cells are more educated to mount 
an elective response to a second challenge and lead to compartmentalisation. It 
is known that IL-12 enhances IFN- production that has a protective role in 
tuberculosis 17. In turn, IFN gamma stimulates TNF alpha secretion that brings 
about the pro inflammatory response in tuberculosis. 
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                   Figure E.  Levels of IFNα, ΤΝFγ, IL-12 and IL-4 in  
                                    tuberculosis patients in Plasma and PF 
(Mean and SEM are represented in the graph; Statistical significance is marked 
by *) 
 
Together these cytokines are concentrated in the PF suggesting that these 
cytokines have important role in immunological resistance to tuberculosis, at 
the site of disease. 
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Figure F.  Levels of IFNα, ΤΝFγ, IL-12 and IL-4 in  
                 Non tuberculous patients in Plasma and PF 
      (Mean and SEM are represented in the graph;  
                  Statistical significance is marked by *) 
On the other hand, IL-4, which is an anti-inflammatory cytokine that acts 
antagonistically to IFN- γ was decreased in PF of TB subjects. This decrease in 
IL-4 concentration may indirectly compel the need for the enhancement of 
protective TH1 immune response. 
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The in vitro cytokine response of the TB patients showed that the IFN- 
gamma levels increased in PFMC when compared with the PBMC in all 
stimulated conditions.  
 
Interestingly, the IL-4 levels in all the stimulated conditions of PFMC 
were also significantly higher than the control levels (Fig. F). However, the IL-
4 levels of PBMC in both stimulated and unstimulated conditions were almost 
similar and comparable to the PFMC control level and did not exhibit any 
prominent variation. This shows that the in vitro cytokine response shifts 
towards a TH0/TH1 type.  
 
Thus, there is a differential T helper response in TB. This increase in IL-
4 production in response to M. tuberculosis possibly influences the sensitization 
of T lymphocytes to apoptosis by a TNF alpha mediated pathway as suggested 
by Rook et al.  
 
This study was able to delineate the correlates of protective immunity in 
TB at the local and at the peripheral level. Our results demonstrated that there is 
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selective TH1 response at the site of infection that is protective. This agrees 
with the previous studies concluding similar results 24-27 
 
However, further experiments have to be performed to show that T cells 
that are programmed to death are activated and to end the critical concentration 
of PPD that affects the T cell proliferation but not apoptosis and vice versa. 
These studies would help us to understand the antigen interaction with 
immunoreactive cells that would benefit protective response to host and thus 
form the basis for the vaccine construction. 
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Conclusion 
 
1. In this study, we confirmed that cytokine status and T-cell reactivity 
within the tuberculous pleural effusions were polarized strongly toward a 
Th1 response. 
2. Compartmentalisation of lymphocytes in pleural effusion occurs in the 
lymphocyte population in cases of tuberculous pleural effusion. 
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The future  
Immunotherapy 
            This is perhaps the most important issue facing workers in the field of 
tuberculosis. As outlined earlier, DOTS helps, but fails to solve the problem, 
and Multidrug-resistant disease is an increasing threat. Immunotherapy is the 
only solution, and the need for this approach has been recognized since the time 
of R. Koch.  
One potential approach to immunotherapy is the direct use of cytokines in 
patients, either systemically, or given by aerosol. IL-2, IFN γ, IL-12 and GM-
CSF have all been investigated. Their potential roles in therapy, other than as a 
potential adjunct to drug treatment in multiresistant cases, have yet to be 
elucidated.  
                     
Another approach that gives striking results in mice is the use of DHEA 
or of the very similar androstenediol. These compounds oppose a subset of the 
effects of glucocorticoids, and can reverse the switch towards Type 2 cytokine 
profile in Balb/c mice, but this has not been tested in man.  
 58
Numerous works are being done in elucidating the unknown markers of 
mediators of apoptosis of Th1 cells in tuberculosis which is mediated by CD 95 
cells. These research will throw more light on the immunology of tuberculosis 
and may be within a short period immunotherapy may play a pivotal role in 
tuberculosis. 
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Proforma 
 
Name    : 
Age     : 
Sex     : 
Cough    :    Y/N         Duration 
Evening rise of Temperature   :    Y/N         Duration 
Loss of Appetite   :    Y/N         Duration 
Loss of Weight   :    Y/N         Duration 
BCG vaccination   :    Y/N 
Contact History   :    Y/N 
Diabetes Mellitus   :    Y/N 
HIV  By ELISA   :    Y/N 
Steroids Use   :    Y/N 
Systemic Illness   :    Y/N        (If yes, in detail) 
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Pleural Fluid   : 
     Biochemical   :   Sugar 
                                                     Protein 
                                                     LDH 
     Cytology   :   Cell Count 
                                                     Malignant cells 
     Microbiology             :   Gram Stain 
                                   AFB Stain    
     PCR 
     Culture by BACTEC 
    FACS    :    CD3, CD4, CD8, CD16, CD56 
   Cytokines                             :    INF γ, ΤΝF α, IL-4, IL-12 
Blood    :    CD3, CD4, CD8, CD16, CD56 
     :    INF γ, ΤΝF α, IL-4, IL-12 
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  Master Charts 
TB  PB AGE SEX IFN γ 
TNF 
α IL 12 IL 4 CD3 CD19 CD4 CD8 CD16+56 CD4/CD8 
 42 M 35.8 32.7 79.4 28.7 44.72 4.65 43.06 23.37 40.54 1.84 
 39 F 33.9 33.7 89.9 27 71.61 3.97 32.17 28.4 14.13 1.13 
 55 M 48.8 35.1 109.3 18.8 74.82 15.21 30.83 33.76 11.62 0.91 
 56 M 65.9 20.7 72.5 32.8 85.55 1.4 22.4 47.9 32.98 0.47 
 52 F 38.2 22.9 84.9 21.5 61.46 1.29 28.9 57.41 18.94 0.50 
 49 M 45.1 19.6 76.4 23.8 73.37 2.94 19.23 48.94 1.46 0.39 
 62 M 35.2 45 78.9 27.7 79.76 9.16 14.62 2.89 19.7 5.06 
 56 M 30.2 22.8 74 23.9 35.54 7.98 9.19 31.62 15.9 0.29 
 51 F 39.6 20.5 75.9 23.4 63.9 5.5 24.5 34.3 11.6 0.71 
 49 F 31.7 22.1 88.9 28.4 74.0 6.0 11.5 19.4 17.4 0.60 
 42 M 35.4 22.5 81.9 26.5 73.9 10.3 28.4 39.9 19.4 0.71 
 58 F 39.3 21.3 82.6 30.7 67.9 8.64 31.96 33.90 25.98 0.94 
 62 M 34.2 25.4 88.2 24.8 87.18 7.98 28.97 38.72 6.94 0.75 
 61 M 37.1 21.9 70.3 24.6 70.37 10.9 27.27 29.4 23.93 0.93 
 59 M 32 19.6 73.7 21.3 60.86 11.8 28.64 31.74 12.36 0.90 
 55 F 35.9 28.4 71.9 24.8 78.03 8.75 19.64 32.78 16.74 0.60 
 59 M 26.9 24.5 70.3 25.8 55.97 9.4 38.53 38.27 10.47 1.01 
 54 M 40.7 23.6 92.8 27.4 49.28 8.96 25.5 27.49 13.52 0.93 
 64 M 35.9 25.4 82.9 24.9 56.91 10.68 29.7 30.28 12.6 0.98 
 65 F 36.8 24.6 82.5 23.4 63.67 11.94 28.05 36.48 14.2 0.77 
 57 M 45.9 23.7 89.3 25.4 61.58 9.73 32.05 38.91 8.6 0.82 
 50 M 24.7 25.9 93.3 27.4 67.96 9.38 20.57 30.48 17.5 0.67 
 53 F 41.8 24.9 80.2 24.6 63.72 9.85 22.63 30.42 14.2 0.74 
 60 F 34.2 25.3 73.8 23.8 66.49 7.43 27.53 51.93 19.3 0.53 
 49 F 36.8 23.5 72.9 24.7 63.26 6.9 29.74 38.49 13.6 0.77 
 62 M 33.9 26.9 72.8 25.5 69.73 12.8 27.94 29.47 15.2 0.95 
 58 M 32.1 29 60.2 24.6 75.38 11.5 26.9 20.38 12.76 1.32 
 51 F 27 29.6 87.9 24.8 61.95 6.95 23.49 19.7 13.53 1.19 
 53 M 63.8 26.6 83.9 30.4 58.05 8.5 22.84 14.8 19.39 1.54 
 63 F 29.7 38 72.9 19.5 65.95 9.6 19.84 30.5 15.02 0.65 
             
mean_1   37.62 26.19 80.48 25.36 66.09 8.34 25.89 32.40 16.32 0.99 
SD_1   9.19 5.78 9.56 3.08 11.13 3.25 7.12 11.09 7.41 0.84 
             
             
Z   -3.58 -4.10 5.71 1.17 -1.02 -1.39 -0.93 1.46 3.99 -0.41 
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TB 
PF AGE 
S
E
X IFN γ 
TNF 
α IL 12 IL 4    CD3 CD19 CD4 CD8 CD16+56 CD4/CD8 
 42 M 100.5 87.4 294.7 21.8 74.98 4.37 61.51 18.79 5.15 3.27 
 39 F 98.7 89.4 305.8 23.8 82.38 2.58 58.82 25.94 7.45 2.27 
 55 M 99.5 88.4 287.6 20.6 85.7 2.44 51.83 27 9 1.92 
 56 M 130.8 84.9 294.9 18.3 83.27 1.65 54.19 21.38 4.03 2.53 
 52 F 88.8 90.2 279.5 17.9 88.23 4.35 59.35 18.38 4.14 3.23 
 49 M 104.5 110.3 296.9 21.8 81.85 8.47 72.73 11.16 2.25 6.52 
 62 M 93.8 78.3 310.9 19.6 71.17 12.92 42.85 22.9 3.28 1.87 
 56 M 94.3 75.9 280.5 21.4 87.13 1.95 73 24 2.83 3.04 
 51 F 107.9 83.4 278.9 21.4 81.84 4.32 57.36 31.83 4.98 1.80 
 49 F 108.7 87.9 293.4 23.8 79.39 5.93 59.92 29.17 5.38 2.05 
 42 M 108.3 82.3 290.4 22.1 87.47 6.03 73.69 21.73 5.93 3.39 
 58 F 96.7 80.4 291.8 18.3 74.73 7.47 72.48 19.35 4.37 3.75 
 62 M 93.6 92.8 289.9 19.8 80.24 8.62 63.45 19.47 5.05 3.26 
 61 M 104.6 87.4 290.4 18.4 87.35 10.84 54.37 26.67 3.49 2.04 
 59 M 99.5 92.5 298.9 23.9 74.85 13.05 56.93 25.71 4.27 2.21 
 55 F 95.7 93.4 289.7 20.5 72.29 9.73 51.93 20.39 5.39 2.55 
 59 M 104.6 90.3 302.1 22.6 60.71 7.39 60.38 21.38 6.39 2.82 
 54 M 103.5 95.5 294.8 22.3 63.89 5.29 52.75 23.27 5.05 2.27 
 64 M 102.4 82.9 310.2 20.5 69.37 6.22 59.86 20.04 5.37 2.99 
 65 F 104.7 98.5 304.8 22.4 72.37 8.41 64.79 16.37 4.38 3.96 
 57 M 94.5 105.9 298.5 19.4 71.48 4.82 70.26 19.27 5.12 3.65 
 50 M 94.7 94.8 305.6 20.4 72.39 5.93 73.49 15.48 4.83 4.75 
 53 F 98.4 88.5 296.9 21.5 73.84 7.48 71.38 13.27 4.36 5.38 
 60 F 105.6 93.9 298.5 22.9 74.26 3.73 70.82 15.47 5.27 4.58 
 49 F 104.6 92.7 302.6 28.4 71.38 2.97 53.96 15.83 4.27 3.41 
 62 M 106.4 93.8 301.8 17.4 73.83 3.85 52.73 23.28 5.25 2.27 
 58 M 103.2 81.8 294.7 19.5 78.35 4.73 57.48 22.18 4.38 2.59 
 51 F 93.5 93.4 294.8 16.9 83.17 5.38 62.52 18.37 4.16 3.40 
 53 M 98.5 93.8 294.7 21.6 60.24 4.27 63.71 19.36 4.97 3.29 
 63 F 100.5 78.9 295.7 18.5 58.73 3.59 62.83 21.39 5.38 2.94 
             
Mean   101.37 89.65 295.6 20.92 75.90 5.96 61.38 20.96 4.87 3.13 
SD   7.61 7.65 8.03 2.41 8.24 2.99 8.04 4.63 1.28 1.09 
             
             
Z   29.20 31.98 132.8 13.08 2.59 -0.32 3.66 -3.90 -3.45 6.90 
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NTB  
PB AGE SEX IFN γ 
TNF 
α IL 12 IL 4 CD3 CD19 CD4 CD8 CD16+56 CD4/CD8 
 56 M 45.4 30 70 24 78.73 2.21 38.46 31.97 15.6 1.20 
 36 F 42.9 32 69 23 61.2 20.6 16.55 21.25 1.2 0.78 
 63 M 40.3 33 73 25 66.66 3.28 32.23 36.83 17.44 0.88 
 49 M 48.9 31 72 28 60.83 12.05 2.1 1.58 0.96 1.33 
 59 M 43.9 29 75 21 68.1 14 45.45 21.53 1.27 2.11 
 63 M 40.4 28 68 22 67.32 10.428 26.958 22.632 7.294 1.19 
 39 F 41.9 30 69 25 73.59 11.47 31.92 38.74 8.28 0.82 
 53 M 46.2 32 68 28 70.03 9.38 29.37 28.39 10.27 1.03 
 48 F 47.9 33 71 23 65.38 9.74 28.04 34.39 8.37 0.82 
 53 M 51.8 35 72 21 62.37 9.39 19.38 31.28 12.46 0.62 
 58 M 41.7 38 74 22 72.27 12.39 30.12 31.29 9.36 0.96 
 59 M 42.4 31 69 26 63.36 7.49 29.26 29.47 7.38 0.99 
 57 M 43.9 30 70 27 71.94 8 27.38 32.48 9.63 0.84 
 54 F 41.3 33 69 23 70.27 6.87 21.78 38.41 10.49 0.57 
 36 F 43.9 32 66 25 69.24 10.37 31.27 30.28 9.38 1.03 
 58 M 42.6 35 73 21 72.85 12.25 30.28 23.38 10.37 1.30 
 53 M 43.1 27 63 26 60.46 9.39 37.28 21.49 11.86 1.73 
 48 M 41.8 29 65 28 68.58 9.74 28.94 28.49 10.38 1.02 
 52 M 50.5 27 68 26 79.64 8.38 29.38 32.58 16.34 0.90 
             
             
             
             
             
             
             
             
             
             
             
mean_2   44.25 31.32 69.68 24.42 68.57 9.86 28.22 28.23 9.39 1.06 
SD_2   3.36 2.85 3.09 2.43 5.58 3.91 9.05 8.52 4.63 0.37 
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NTB PF AGE SEX IFN γ 
TNF 
α IL 12 IL 4 CD3 CD19 CD4 CD8 CD16+56 CD4/CD8 
 56 M 53.7 26.5 80.4 10.5 80.97 2.05 49.43 26.2 13.71 1.9 
 36 F 55.9 29.6 78.9 9.7 65.84 4.39 52.59 27.8 8.96  
 63 M 59.5 23.6 73.5 12.5 88.29 3.05 54 29.81 7.69 1.8 
 49 M 60.3 27.5 80.4 11.7 83.6 3.59 10.48 10.48 0.87 1.0 
 59 M 52.9 30.5 84.5 13.6 32.88 4.75 18.39 14.42 11.52 1.3 
 63 M 57.9 25.6 80.6 9.7 70.316 3.98 36.978 21.38 8.55 1.7 
 39 F 51.5 21.6 83.4 7.9 67.33 6.35 76.7 35.59 9.47 2.2 
 53 M 58.4 2.6 82.4 13.7 70.44 9.54 64.87 28.56 10.57 2.3 
 48 F 53.7 31.5 75.8 15.7 45.98 6.59 56.49 28.39 8.26 2.0 
 53 M 49.6 27.5 79.6 7.6 38.48 7.48 46.58 27.49 6.59 1.7 
 58 M 51.6 28.6 79.6 9.5 53.8 5.5 34.3 30.2        8.7 1.1 
 59 M 50.6 24.6 82.4 15.7 52.87 7.39 31.83 26.86         2.27 1.2 
 57 M 55.3 23.6 83.5 12.7 35.67 18.39 48.49 28.48 8.49 1.7 
 54 F 57.7 24.7 82.7 13.8 58.98 3.98 63.28 28.39 4.59 2.2 
 36 F 55.8 28.5 80.6 9.6 75.78 5.94 48.38 28.49 5.93 1.7 
 58 M 53.7 29.5 78.4 10.5 74.38 9.39 49.93 32.4 3.69 1.5 
 53 M 57.4 27.4 83.7 11.6 67.94 3.47 45.87 34.89 7.63 1.3 
 48 M 53.6 25.3 80.5 11.5 79.46 5.96 50.25 36.7 8.49 1.4 
 52 M 48.6 25.4 84.6 13.6 85.85 7.49 52.83 40.94 6.95 1.3 
             
             
             
             
             
             
             
             
             
             
             
Mean   54.62 25.48 80.82 11.64 64.68 6.28 46.93 28.29 7.52 1.63 
SD   3.37 6.12 2.89 2.36 17.21 3.59 15.54 7.13 3.10 0.39 
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